Skip to content

A prospective, randomised, controlled trial to study the effect of verapamil and adenosine on the TIMI frame count

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN44611940
Enrollment
105
Registered
2006-09-29
Start date
2003-05-07
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urological and Genital Diseases: Angiography and/or angioplasty Urological and Genital Diseases Angiography and/or angioplasty

Interventions

Patients undergoing coronary angiography with a view to urgent or emergency angioplasty will be consented and will be given a patient information leaflet. Patients will be randomised if their coronar

Sponsors

Record Provided by the NHSTCT Register - 2006 Update - Department of Health
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 35 in each group, total 105 patients undergoing angiography and/or angioplasty in the setting of an acute coronary syndrome. Patients will be randomised if their coronary arteries show evidence of the slow-flow phenomenon and all patients undergoing angiography and/or angioplasty in the setting of an acute coronary syndrome will also be randomised. Patients who are listed for elective or emergency angiography and/or angioplasty will be suitable for the study.

Exclusion criteria

Exclusion criteria: 1. Asthmatics 2. Patients with renal impairment 3. Those with left main stem disease 4. Patients with a BP100 bpm 5. Patients with heart block

Design outcomes

Primary

MeasureTime frame
1. Improvement in TIMI frame count. 2. Post-procedural left ventricular function (measured by echocardiography). 3. Speed and extent of ST segment recovery. 4. Cardiac enzyme measurements.

Secondary

MeasureTime frame
Not provided at time of registration

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026